



**Outpatient Medical Injectable
Ocrevus Authorization Request Form
Fax to 833-581-1861
(Medical Benefit Only)**

Member Name: _____ DOB: _____

Member ID (UMI): _____ Medicare Commercial

Address: _____

ORDERING/ATTENDING PROVIDER

Physician Name: _____ NPI: _____

Address: _____

Office Contact: _____ Phone Number: _____ Fax Number: _____

SITE OF CARE

Place of Service (please select one)

Home Infusion Office – Professional Ambulatory Infusion Suite – Professional Outpatient Hospital

Is the site of care affiliated with a hospital or will the claim be billed as a facility claim? Yes No

Place of Service Name: _____ NPI: _____ Tax ID: _____

Address: _____

Drug Supplier (please select one)

Supplied by a Specialty Pharmacy (for Home Infusion, Office – Professional, or Ambulatory Infusion Suite – Professional) Pharmacy Name: _____ Pharmacy NPI: _____

Buy & Bill (for Office – Professional or Outpatient Hospital administration)

DRUG/DIAGNOSIS INFORMATION

Drug Name: **OCREVUS** Strength or Dose: _____ Date of service: _____

Directions: _____ Quantity (# of doses/visits): _____

Diagnosis code (ICD10): _____

****Please verify member’s eligibility and benefits through the health plan****

Diagnosis Description (check one)

Relapsing Form of Multiple Sclerosis

(Includes relapsing-remitting, active secondary progressive disease or clinically isolated syndrome)

Primary Progressive Multiple Sclerosis based on the McDonald criteria

Note: McDonald criteria defined as: One or more years in which neurologic symptoms typical of multiple sclerosis progressively worsen and at least 2 of the following:

- Evidence of lesion dissemination in space in the brain based on greater than or equal to 1 T2 lesions in at least 1 area characteristic for MS periventricular, juxtacortical, or infratentorial; Gadolinium enhancement of lesions is not required; **or**
- Evidence of lesion dissemination in space in the spinal cord based on greater than or equal to 2 T2 lesions in the cord (Gadolinium enhancement of lesions is not required); **or**
- A documented history or presence of an elevated CSF IgG index or CSF oligoclonal band

Other: _____

CLINICAL INFORMATION

Does the member have documentation of an MRI of the brain showing abnormalities consistent with multiple sclerosis? YES NO

Is Ocrevus prescribed by or in consultation with a neurologist or provider who specializes in the treatment of multiple sclerosis? YES NO

Does the member have an active Hepatitis B virus infection? YES NO

Will the member receive any **LIVE** vaccines 4 weeks prior to and during treatment with Ocrevus?
 YES NO

Has the member had a life-threatening infusion reaction to Ocrevus? YES NO

New Start

Continuation of Therapy

Date of last infusion: _____

Please attach all pertinent clinical information

Attached: YES NO

This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware, and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.